Rights Issue Closed
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Biotron Limited has announced the successful completion of its renounceable rights issue, which has now closed, raising funds before costs. The funds raised will support the company's commercialization activities and ongoing operational costs, particularly for its antiviral programs. The announcement has been approved by the Board of Directors and reflects strong support from shareholders and management.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/rights-issue-closed
Story so far
Earlier from Biotron
- Replacement Prospectus
- Response to ASX Query Letter
- Supplementary Prospectus
- Response to ASX Aware Query
- Prospectus
Later from Biotron
- Full Year Statutory Accounts and Appendix 4E
- Pause in Trading
- Trading Halt
- Acquisition of Sedarex Limited and $2.5m capital raising
- Non-Renounceable rights Issue Prospectus
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron